10X Genomics (TXG) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic vision and market opportunity

• Focused on accelerating biological understanding through high-resolution, scalable tools for single-cell and spatial analysis, transforming research across all fields of biology, with over 10,000 high-impact publications.

• Addressable market estimated at $13B for adjacent labs and $21B for all life science research, with significant room for growth from mainstream biology, translational research, and biopharma.

• Biopharma revenue is targeted to grow from 15–20% to 50% of overall business, supported by product innovation and cost reductions.

• Expansion opportunities include academia, translational research, and especially biopharma.

• Product innovation and lower-cost offerings are key levers to drive market expansion and routine use.

Product innovation and launches

• Launched multiple new products across all three platforms in 2024, including Chromium GEM-X, Visium HD, Xenium 5K, and Xenium Prime 5K.

• New products offer improved performance, lower costs, and expanded applications, enabling million-cell experiments and $0.01 per cell cost.

• Spatial platforms Visium and Xenium saw 33% YoY growth, with $179M in revenue and 1,200+ cumulative instruments sold, driven by new launches.

• Platforms now support FFPE samples and integrate with standard pathology workflows, broadening translational and clinical research applications.

• All new launches received strong customer feedback and are expected to drive future growth.

Commercial and operational execution

• Scaled global sales and support teams, with a major reorganization transitioning over 40% of U.S. accounts in Q3 2024 to align with product diversity and customer types, especially in biopharma.

• Operational investments ensure high quality, consistency, and supply chain control, supporting expansion into more stringent markets.

• Commercial reorg is on track, with full capacity expected by mid-2025.

• Budget flush in Q4 2024, especially in biopharma, contributed to revenue outperformance.

• New specialized sales organization aims to accelerate Xenium adoption and drive outsized growth in biopharma.